Simultaneously, nicotinamide phosphoribosyl transferase (NAMPT), the rate limiting enzyme in NAD+ biosynthesis, is overexpressed in a number of cancers36–38 and its expression has been associated with tumor progression in patients39, rendering NAMPT an attractive therapeutic target40. Here, NAMPT is linked to neoplasm.